Lynn Markowitz

M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First‐in‐Human Study

Leona Ling, Jan Hillson, Renger G. Tiessen et al. · Clinical Pharmacology & Therapeutics · 2018 · 152 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors

Daniel Ortiz, Jonathan C. Lansing, Laura I. Rutitzky et al. · Science Translational Medicine · 2016 · 66 citations

Life Sciences, Immunology, Medicinal Chemistry +14

Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties

Nilufer P. Seth, Rui Xu, Matthew L. DuPrie et al. · mAbs · 2025 · 30 citations · Full text

Life Sciences, Immunology, Pharmacology +17

An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses

Eva Gutiérrez, Mitchell Bigelow, Colin LaCroix et al. · Med · 2023 · 19 citations

Life Sciences, Immunology, Pharmacology +17

M281: A Therapeutic Anti-FcRn Blocking Antibody for Rapid Clearance of IgG and IgG Autoantibodies in Immune Cytopenias and Other Auto/Allo-Immune Disease

Leona Ling, Sucharita Roy, Thomas M. Daly et al. · Blood · 2015 · 11 citations

Life Sciences, Immunology, Pharmacokinetics +16